| Autor: |
Peila C; Neonatal Unit, Department of Public Health and Pediatrics, University of Turin, Turin, Italy., Spada E; Neonatal Unit, Department of Public Health and Pediatrics, University of Turin, Turin, Italy., Deantoni S; Neonatal Unit, Department of Public Health and Pediatrics, University of Turin, Turin, Italy., Borsani M; Neonatal Unit, Department of Public Health and Pediatrics, University of Turin, Turin, Italy., Asteggiano M; Neonatal Intensive Care Unit, Maria Vittoria Hospital, Turin, Italy., Chiale F; Neonatal Intensive Care Unit, Maria Vittoria Hospital, Turin, Italy., Moro GE; Italian Association of Human Milk Banks, Milan, Italy., Giribaldi M; Institute of Sciences of Food Production, National Research Council, Grugliasco, Italy., Cavallarin L; Institute of Sciences of Food Production, National Research Council, Grugliasco, Italy., Cortinovis I; Laboratorio GA Maccacaro, Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy., Coscia A; Neonatal Unit, Department of Public Health and Pediatrics, University of Turin, Turin, Italy. |
| Abstrakt: |
Background: Since human milk contents does not meet the high need of very low birth weight infants, fortification of breast milk is a standard practice for this population. As donkey milk has been long considered for children allergic to cow's milk proteins due to its low allergic properties, a new donkey milk-derived fortifier (DF) has been recently evaluated as a valid alternative to bovine milk-derived fortifier (BF). It seems to improve feeding tolerance when compared with standard BF, with similar neurodevelopmental and auxological outcome at 18 months of age. The aim of this study is to evaluate the development of allergic manifestations occurring in the population of the "Fortilat Trial" at 6-8 years of age. Methods: Allergic manifestations were assessed by an ad hoc questionnaire administered to families. The occurrence of asthma, allergic rhinitis and oculorhinitis, rashes and atopic dermatitis, food allergies, accesses to an emergency department for allergic reactions, and the need of antihistamine have been investigated. Results: In total, 113 infants were enrolled in the study (BF arm: n = 60, DF arm: n = 53). No difference in risk was observed between the two groups for all the considered outcomes. In conclusion, our data suggest that DF does not impact the development of allergic manifestations in the first years of life. Clinical Trial Registration number: ISRCT N70022881. |
